AMA Pushes Congress to Rein In AI Chatbots in Medicine
The American Medical Association is urging federal lawmakers to strengthen safeguards for AI chatbots used in healthcare. The move underscores growing concern that consumer-facing tools are moving faster than standards for oversight, accuracy and liability.
The AMA’s call for stronger safeguards signals that medical organizations are no longer treating AI chatbots as a novelty issue. Chatbots increasingly sit at the boundary between wellness advice, symptom checking and clinical decision support, which makes their errors harder to contain and their harms harder to attribute.
The policy concern is not simply that chatbots can be wrong. It is that they can be confidently wrong in contexts where users may defer to them instead of seeking care. That creates a risk profile unlike traditional consumer software: misleading guidance can delay treatment, amplify anxiety or encourage unsafe self-management.
For regulators, the challenge is that the chatbot market moves faster than formal oversight. Systems can be repurposed, updated or embedded into workflows faster than many existing medical device frameworks can track. The AMA’s intervention suggests the profession wants clearer lines around what counts as clinical advice, what disclosures are required and who is responsible when AI crosses that line.
This is also a strategic moment for healthcare AI vendors. Trust may become a competitive moat. Companies that can prove transparent prompting, evidence-grounded responses, escalation pathways and human oversight may have a better chance of winning clinical adoption than those that simply optimize for conversational fluency.